October 2010 in “Journal of Men's Health” Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.
305 citations
,
March 2008 in “AJP Endocrinology and Metabolism” SSAT is a key enzyme affecting cell growth and metabolism, with potential but risky use in disease treatment.
130 citations
,
November 2017 in “Frontiers in Immunology” The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.
111 citations
,
August 2002 in “Journal of Medicinal Chemistry” New compounds were made that block an enzyme linked to breast cancer better than existing treatments.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
42 citations
,
June 2020 in “Seminars in Oncology” Sex hormones may affect COVID-19 severity, with men often faring worse, and targeting related pathways could offer treatment options.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
32 citations
,
February 2017 in “Oncotarget” Cellular senescence has both cancer-blocking and cancer-promoting effects, and targeting senescent cells may improve health and lifespan.
23 citations
,
January 2017 in “Current Rheumatology Reports” Unique fat cells near fibrotic areas contribute to systemic sclerosis progression.
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.